IMMUNOLOGYMEET2023

Jacques Pouysségur, CNRS Research Director Emeritus, graduated from an Engineering School in Biochemistry at the University of Lyon, where he obtained his Ph.D. in 1972. He spent two years as a post-doctoral scientist at the National Cancer Institute of NIH (USA) and established his own research group in 1978 at the CNRS Biochemistry Centre of the University of Nice. After directing the CNRS Institute of Signalling, Developmental Biology and Cancer Research up to 2008, his team joined the new Research Institute of Cancer & Aging (IRCAN) in Nice and the Biomedical Department of the Centre Scientifique of Monaco (CSM). Jacques Pouysségur has previous experience in bacterial and somatic cell genetics, metabolism, Na-H exchanger, pH regulation, G protein-coupled receptors, and MAP kinase signaling in the context of growth control in mammalian cells. In the last 25 years, his group developed a strong interest in hypoxia signaling, oxygen and nutrient sensing, angiogenesis, autophagy amino-acid transporters, oxidative stress, cancer metabolism, Warburg effect, and immune suppression. He is a member of AACR, EACR, EMBO, the French and European Academy of Sciences, and the past President of the International Advisory board of the National Cancer Institute.

Gregory A. Buck, Ph.D., Professor of Microbiology and Immunology & Computer Science at VCU, obtained a BS in Genetics from the University of Wisconsin-Madison, an MS and Ph.D. in Microbiology and Immunology from the University of Washington-Seattle studying the toxinogenic bacteriophages of Corynebacterium diphtheriae, and did a postdoctoral at the Institut Pasteur in Paris studying the molecular biology of antigenic variation in African Trypanosomes. After joining the faculty of Microbiology and Immunology at VCU, Buck continued to work on the novel mechanisms of gene expression in kinetoplastid protozoa. In parallel, he founded VCU’s Genomics Core and VCU’s Center for High-Performance Computing. He founded the Center for the Study of Biological Complexity, with its undergraduate and graduate programs in bioinformatics, in 2000, and directed that unit until 2017. In 2019, Buck launched the Center for Microbiome Engineering and Data Analysis, with an institution-wide focus on microbiome science. Dr. Buck’s research has recently focused on microbial genomics and the human microbiome through support from the National Science Foundation’s Assembling the Tree of Life program and the National Institutes of Health Human Microbiome Program. Much of his recent research has focused on dissecting the role of the vaginal microbiome on women’s gynecologic and obstetric health. In the past two years, Dr. Buck has studied the evolution of SARS-Cov-2, the human microbiome, and its impact on disease severity in the Midatlantic region of the United States.

Ljudmila Stojanovich received her Ph.D. in Medicine, with the thesis “Neuropsychiatric manifestations in patients with Systemic Lupus Erythematosus” in 1999. Dr. Stojanovich’s research focuses on Systemic Lupus Erythematosus, Antiphospholipid Syndrome, and Vaccination in patients with Autoimmune Rheumatic diseases. She is an author of three monographs and of about 250 articles on various aspects of Autoimmune Rheumatic disorders, published in international and domestic journals and in conference proceedings. She is in Editorial Boards (Editorial Boards LUPUS (LONDON). /Reviewer in the “CURRENT CONTENTS” or “Science citation index”, like LUPUS REVIEWER DATABASE, Cellular, and Molecular Neurobiology, The Journal of Vaccine

Eric Vivier, DVM, Ph.D., is a Professor of Immunology at Aix-Marseille University and at the Public Hospital of Marseille (AP-HM). In addition, he was appointed in 2018, as Scientific Director of Innate Pharma, a biotechnology company dedicated to improving cancer treatment with innovative therapeutic antibodies that exploit the immune system (https://www.innatepharma.com/). He completed his post-doctoral training at Harvard Medical School, then joined Aix-Marseille University as a professor at the Centre d'Immunologie de Marseille-Luminy (CIML) in 1993 before becoming its director from 2008 to 2017. He is also one of the founders of MarseilleImmunopôle, an immunology cluster created in 2014 linking fundamental and therapeutic research, innovation, and industrial development on the Aix-Marseille Metropole (https://marseille-immunopole.org/) Eric Vivier's work focuses on innate immunity and in particular Natural killer and other innate lymphoid cells, at Ciml, at AP-HM, and at Innate-Pharma. Professor Vivier has published over 400 scientific articles and is on the list of the most cited researchers: https://recognition.webofscience.com/awards/highly-cited/2021/ A laureate of the European Research Council (ERC advanced grants), a member of the EMBO, the Académie Nationale de Médecine and the Institut Universitaire de France, Prof. Vivier has received several awards including those from the Ligue Nationale contre le Cancer (and the European Federation of Immunological Societies (EFIS). He is Chevalier de la Légion d’Honneur and Officier de l’Ordre National du Mérite. He is also President of the Paris Saclay Cancer Cluster Association

Dr. Galon received his Ph.D. in immunology in 1996 and undertook his postdoctoral work at the U.S. National Institutes of Health (NIH) in Bethesda, Maryland. Since 2001, he has worked at the Cordeliers Research Center in Paris, France, where he has been the director of the INSERM Laboratory of Integrative Cancer Immunology since 2009. His work aims to provide a better understanding of the tumor microenvironment and the dynamics of the immune response in human tumors. His laboratory has identified and demonstrated the importance of the immune contexture when considering cancer treatment. He defined the Immunoscore as a new method for routine clinical assessment of prognosis of cancer patients.

Dr. Indre Plestyte – Butiene, general pediatrician, pediatric pulmonologist, Ph.D. in allergy and immunology since 2013. Assoc. Professor of Klaipeda University (Lithuania), Faculty of health sciences, CEO of a network of pediatric clinics „Mama, I am ill„ in Lithuania. An experienced pediatrician with a strong interest in children's immunology, microbiota, allergology, and lung diseases. Lecturer, researcher, and motivational speaker, author of the book „Why children get sick and how we can help them “. Her work aims to provide a better understanding of the immune system development in childhood and its crosstalk with microbiota, delivering lectures on Environmental health, the impact of the natural environment (pollution of air, water, soil, anthropogenic food pollution, microbes), meteorological and climatic factors, home environmental and psychosocial health of affected populations to prevent diseases and health affections. High interest is indicated in healthy nutrition, and alimentary physical, chemical, and biological safety.

Vladimir Muzykantov obtained his MD from First Moscow Medical School (Internal Medicine, 1980) and was a researcher at Russian National Cardiology Research Center where he received Ph.D. (Biochemistry, 1985). In 1993, he joined PENN where he is a Professor and Vice-Chair of the Department of SPATT since 2011. He is the Founding Director of the CT3N, which he directs since 2010. Muzykantov works on targeted drug delivery: A) Identification of targets; B) Design of carriers; C) Deciphering biological factors modulating targeting; D) Testing pharmacokinetics, biodistribution, sub-cellular addressing, activity, and effect in animal models of human pathology. His contributions include A) Vascular targeting of drugs including therapeutic RNA to lungs and brain; B) Discovery of endocytosis of nanocarriers via non-internalized receptors; C) Targeting of enzymes in semi-permeable carriers; D) Delivery of drugs and nanocarriers on the surface of red blood cell (RBC) super-carriers. Muzykantov has published ~280 papers in journals including Science, Nature Biotechnology, Nature Nano, Nature Communications, PNAS USA, Blood, and ACS Nano (h-index 77). He holds a portfolio of IP and pursues their development. Muzykantov was the PI of numerous NIH RO1 grants and several industrial SRA. His current portfolio includes non-modular R01s "Vascular delivery of nanocarriers by erythrocytes" (2018-2023), "Vascular targeting of nanocarriers for RNA" (2020-2025), "Dual drug delivery to lung/blood interface in respiratory infections" (2021-2026), "BC-mediated delivery thromboprophylaxis" (2021-2026). Muzykantov's services include ad hoc reviewing for about 120 journals and 30 funding agencies including national funding agencies of Israel, Canada, Switzerland, Austria, Finland, The Netherlands, Italy, Hong Kong, Cyprus, France, the UK, and Ireland. He served on several NIH special review panels, ad hoc of many Study Sections, and chartered member of the Nano Study Section (2015-2019). Muzykantov is a recipient of the Established Investigator Award (1996-2000) and Bugher Stroke Award (2000-2004) from the American Heart Association (AHA). He gave numerous talks at diverse GRCs: Drug carriers (2002, 2008, 2016), Oxidative stress (2004), Endothelium (2004), Biomaterials (2015), and Plasminogen (2018). He organized/chaired the Transatlantic Conference on Targeting Molecular Signatures in Lungs (Luzerne, 2009), GRC on Drug Carriers (elected co-Chair with Joe DeSimone in 2012), HLBI Division of Lung Diseases Workshop “Precision Therapeutics Delivery for Lung Diseases” (2014). He was the Keynote speaker at recent national and international conferences in Turkey, Italy, FRG, and Israel. The Controlled Release Society elected him to the College of Fellows (2022). Muzykantov was a recipient of Dr. Jane Glick's Award for Graduate Teaching at PENN School of Medicine (2012). He served two terms as the Chair of the Pharmacology Graduate Group (2006-2012) and received the Award for Distinguished PGG Faculty (2012). Among his former trainees are Tom Dziubla (Endowed Chair of Bioengineering, U. Kentucky), Silvia Muro-Galindo (ICREA Professor, Barcelona, Spain), Irina Balyasnikova (Associate Professor, NWU, Chicago), Marc Ilies (Professor, Temple U), Carmen Garnacho (Vice Dean of School of Medicine, University of Seville in Spain), Bisen Ding (Associate Professor of Icahn Mount Sinai School of Medicine, NY, a winner of the Blavatnik Award, 2013), and Jake Brenner (Assistant Professor UPENN).

Dr. Taylor Doherty is a Professor of Medicine and interim Co-chief of Rheumatology, Allergy, and Immunology at the University of California, San Diego. His laboratory is funded by the National Institutes of Health and Veterans Affairs with the goal to identify novel mechanisms that control innate lymphoid cells during type 2 inflammation. His work was the first to demonstrate that leukotrienes, lipid mediators that are elevated in asthma and allergic diseases, activate lung ILC2s to promote type 2 inflammation. His translational projects using patient samples identified potential roles for ILC2s in allergic rhinitis, nasal polyposis, aspirin-exacerbated respiratory disease (AERD), and eosinophilic esophagitis. In addition to his laboratory studies, he cares for patients with asthma and allergies in weekly clinics at UCSD and the VA. He is a fellow of the American Academy of Asthma, Allergy, and Immunology (AAAAI) and currently serves as chair of the Basic Sciences Workgroup. Finally, he is co-director of the interdisciplinary UCSD Center for Asthma and Sinus Disease which is a World Allergy Organization center of excellence that is dedicated to advancing clinical care, research, and training in airway disorders.

Jessy Deshane received her Ph.D. in Biochemistry and Molecular Genetics from the University of Alabama at Birmingham under the mentorship of Dr. Anupam Agarwal. After completing her post-doctoral training in Immunology with Dr. David Chaplin, in the Department of Microbiology, she joined the faculty of the Division of Pulmonary, Allergy, and Critical Care Medicine in the Department of Medicine in 2011 as an Assistant Professor. Dr. Deshane is committed to an academic career combining basic and translational research with an emphasis on inflammatory diseases of the airway. Research in Dr. Deshane’s laboratory is focused on myeloid-derived regulatory cells (MDRCs) and their immunoregulatory roles in chronic inflammatory lung diseases. Dr. Deshane is particularly interested in delineating mechanisms underlying the differentiation, activation, metabolism, and function of MDRCs. Her group recently reported that a subset of reactive oxygen species (ROS)-producing MDRCs exacerbate T cell responses and airway hyper-reactivity in mice. They recently characterized human MDRC subsets in bronchoalveolar lavage of asthmatics.

Dr. Vijayanand’s lab employs genomics tools to understand, diagnose and treat pulmonary disease such as asthma, lung cancer and infectious diseases, including the novel coronavirus. His laboratory has developed a number of techniques to study the molecular profiles of circulating and airway immune cells from patients with asthma and other diseases, using fewer cells than previously possible. Dr. Vijayanand oversees a large-scale effort to map epigenomic modifications in more than a dozen different types of human immune cells from normal individuals to understand how epigenetic variations cause susceptibility to disease. For many human diseases, large-scale genomic studies have identified common genetic variants that occur more frequently in people with cardiovascular, autoimmune, inflammatory and infectious diseases, diabetes and asthma than in those without these diseases. However, it has been difficult to pinpoint which genetic changes are truly relevant to disease, or in what specific cell types the genetic variation has the largest effect on one’s health. Mapping the epigenome will enable scientists to zoom in on those genes with the greatest likelihood to contribute to disease, and the cell types in which they act, and therefore will help identify novel therapeutic targets.

Dr. Roza Nurieva received her Ph.D. from the Gabrichevsky Research Institute of Epidemiology and Microbiology, Moscow, Russia. Her postdoctoral fellowship, which was supported by the Arthritis Foundation, was with Dr. Chen Dong at the University of Washington, Seattle, USA, focusing on understanding the role of costimulatory molecules in regulating T helper cell activation, differentiation, and function. She is currently an Associate Professor in the Immunology Department at MD Anderson Cancer Center. Dr. Nurieva’smain research goals are: 1) To determine the molecular mechanisms whereby immune responses are normally regulated; and 2) To apply this knowledge to the understanding and treatment of autoimmunity, inflammation, as well as cancer. Dr. Nurieva's research group has made important contributions to basic immunology, as well as understanding the role of T cells in autoimmunity, inflammation, and cancer. Moreover, her laboratory current studies might be potent for the treatment of patients who develop distinct organ-specific autoimmune complications after immune checkpoint inhibitor therapy.

Day-Yu Chao received Epidemiology training from National Taiwan University, Taiwan, and molecular biology training from the Centers for Disease Control and Prevention, USA (US-CDC). With years of field-work experiences and influential publications on zoonotic and vaccine-related work, she has been pointed to several academic and government positions, such as Review Editor of “Frontiers in Microbiology”, Top Ten Best Paper with Destructive Innovation” awarded by MOST in 2020, Selected 15 spotlight laboratories in Taiwan by Center for Global Affairs and Science Engagement (GASE), MOST, 2020 and Academic member of Risk Assessment Advisory Committee of Bureau of Animal and Plant Health Inspection and Quarantine (BAPHIQ), Council of Agriculture (COA), Taiwan. Her research interests mainly focus on antigen development for differential diagnosis and vaccine development, the discovery of human monoclonal antibodies with various approaches.

Dr. Magali Irla leads the team “Immune Tolerance & T-cell Differentiation” at the Center of Immunology of Marseille Luminy (CIML), Marseille, France(http://www.ciml.univ-mrs.fr/science/lab-magali-irla/immune-tolerance-and-t-cell-differentiation). She has a long-standing interest in the induction of T-cell tolerance that takes place in the thymus. After a Ph.D. in Immunology at Aix-Marseille University, she completed postdoctoral training at the University of Geneva in Switzerland where she studied the differentiation of medullary thymic epithelial cells(mTECs) that control the selection of developing T cells. After being appointed as a junior group leader at the University of Geneva, she joined the CIML where she continues to study the fascinating interplay between mTECs and developing T cells, including Foxp3+ regulatory T cells.

I am an Assistant Professor of Immunology in the Department of Pediatrics at Weill Cornell Medical College. The overarching goal of our research is to identify and define gut microbiome-regulated immune pathways in early life that impact the long-term health of women and children. To accomplish this goal, my laboratory has developed innovative gnotobiotic mouse models and genetic knockout mice for studies of the development of the immune system and the crosstalk between immune cells and gut bacteria in early life. We have the expertise to isolate and functionally assess or profile the transcriptomes of immune cells and bacteria from various tissues, including the intestine, placenta, lung, and brain, for studies of the interactions between immune cells and gut bacteria in early life immune tolerance, infection, and modulation by diet. Furthermore, by leveraging an infant stool biobank established in our lab, we validate our mouse findings in the human system through metabolomic and metagenomic profiling of human infant stool bacteria as well as gnotobiotic mice that harbor human infant bacteria. Through additional collaboration with research labs with complementary expertise within and outside Weill Cornell Medicine, we employ multi-disciplinary approaches to identifying gut bacteria-based therapeutic targets to treat gut inflammatory or infectious diseases in early childhood.

Professor Razin is a world-leading scientist in the field of mast cell biology. His first major contribution was over 30 years ago, when he developed a cultured mouse bone marrow-derived mast cell model. This system changed mast cell research and is still one of the main tools for studying mast cell function. Around 20 years ago, his group presented a key advancement in the field of cell signaling when they reported a previously unknown the p 207 S LysRS–Ap4A–Hint-1–MITF signaling pathway, which is directly involved in gene regulation in variety of cell types.

I am qualified in paediatrics and trained in paediatric intensive care. I have worked in Poland, Switzerland and in the United Kingdom. I have joined Royal Manchester Children's Hospital in 2019 as a consultant paediatric intensivist. I have a strong interest in research within the area of immunometabolism and human predictive models. I am focusing on developing translational researchinimmunometabolism, immunophenotyping andin patient derived predictive models.The proposed research would integrate interest of many specialities including immunology, metabolic diseases, rheumatology, bone marrow transplant and infectious diseases. I have previously held a Medical Research Council Fellowship (MRC, 2014) to pursue PhD project on “Cellular interactions in innate immunity: Interactions of fibroblasts and myoblasts with mitochondrial dysfunction and immune cells” at Newcastle University. This PhD hypothesis was based on preliminary data from clinical observations and aimed to improve our understanding of the role of mitochondrial dysfunction in inflammatory responses. I was awarded Doctor of Philosophy Degree in July 2018. Since then, I have already applied for several grants and was successfully approved for MAHSC Women & Children’s Domain funding (September 2020) to pursue the research on precision immunometabolic reprogramming of immune cells.

Dr. Yuhao Jiao, M.D., M.Res, is now a physician and postdoctoral fellow at Peking Union Medical College Hospital, Chinese Academy of Medical Sciences. He completed his degree from Tsinghua University and the University of Melbourne. He has a great interest in the field of cancer immunology, mostly focusing on the roles of Innate Lymphoid Cells and their roles in carcinogenesis. He participated in the development of the anti-leukemia drug Venetoclax (ABT-199) and receives royal distributions. His work on optimizing the preconditioning regimen of bone marrow transplantation by manipulating NK cells and studies on depicting the immune landscape of endometrial carcinoma have been widely cited. He is currently working on exploring how NK cells and other subsets of innate lymphoid cells affect the early carcinogenesis of gastrointestinal cancers.

Dr. Diab is a clinical investigator whose research is focused on developing new Immunotherapeutic Strategies that will improve clinical outcomes in patients. Building on his extensive background in immunology in general and tumor immunology specifically, Dr. Diab is leading multiple clinical trials involving novel immune modulator agents for Melanoma. In addition, he is leading a program for Interventional Immunotherapy that was established to develop intratumoral therapeutic and tumor vaccination strategies in combination with Systemic therapy; designed to improve clinical outcomes and allow a better understanding of the dynamics of each patient’s immune response to the tumor.

I am an Investigator and Head of the Laboratory of Autoimmune and Cancer Research at the Feinstein Institutes for Medical Research. I am also a Professor at Hofstra/Northwell School of Medicine. My laboratory specializes in the identification of new signaling pathways and diseases mediated by interferon regulatory factors (IRFs), with specific interests in immune cell signaling and the cellular response to stress. As a postdoctoral fellow, I was the first to clone IRF5 and show that it is an integral regulator of virus-induced type I IFN gene expression. Subsequent studies from our lab implicated IRF5 in the regulation of multiple cytokines/chemokines which has since led to an entire field of study on IRF5 and how dysregulation of IRF5 contributes to disease pathogenesis. Over the years, my lab has contributed extensively to the understanding of IRF5 function in Toll-like receptor signaling, DNA damage signaling, death receptor signaling, B cell receptor signaling, and tumor immunity. We study IRF5 immunoregulatory mechanisms in the context of disease as IRF5 is now widely accepted to be dysregulated in multiple autoimmune diseases, inflammatory diseases, and cancer. A major contribution that we have made and continue to make to the field of IRF5 research is the development, validation, and sharing of reagents and assays that relate to the measurement of IRF5 cellular expression and function (PMC8187113, PMC7228753, PMC3288585). Further, we have consistently served as a resource for the testing and validation of IRF5 antibodies for biological and biochemical assays (PMCID: PMC4969615). Utilizing many of these assays and reagents, we have contributed a significant body of work towards understanding the biologic function of IRF5 in the autoimmune disease systemic lupus erythematosus (SLE). Studies in both mice and humans confirm that IRF5 is a critical regulator of innate and adaptive immunity and that loss or inhibition of IRF5 protects from SLE disease onset and severity. To this end, we have developed the first class of IRF5 inhibitors that are cell-permeable, directly bind to IRF5, and show in vivo therapeutic efficacy in multiple models of murine lupus. In addition, we have contributed extensively to the understanding of IRF5 function in myeloid cells, including monocyte/macrophage polarization and trafficking, intercellular communication, and differentiation to specific inflammatory subsets, termed inflammatory hemophagocytes. Below are related works that support this area of research

Dr. Srinath Balkundhi has completed his Ph.D. in Pharmaceutical Sciences at JNTUA University and Mentor for the postdoctorate scholars. He is working as a professor in Pharmaceutics and Dean, School of Pharmaceutical Sciences Sanjay Ghodawat University Kolhapur Maharashtra, India. He has published more than 25 papers in reputed journals and presented papers at National and International conferences.

Dr. Ravi completed his Internal Medicine residency, MD, and Allergy & Immunology Fellowship at Cleveland Clinic, USA. He was proctor for his internal medicine board exams during his residency, and chief fellow during his fellowship, and graduated in the top ten percent in the country for both his Internal Medicine and Allergy and Immunology board exams. He is American Board Certified in Allergy and Immunology and Internal Medicine. Dr. Ravi was in tertiary referral academic practice at the University of California at Irvine (UCI) with a distinguished career as Head of Adult and Pediatric Allergy clinics and Program Director for Allergy and Immunology Fellowship (the youngest Allergy and Immunology Fellowship program director in the USA). He has mentored many medical students, residents, and fellows and has been President of the Orange County Society of Allergy and Clinical Immunology. He was Head of Immunological Clinical trials, and Clinical Research for his specialty of Allergy and Immunology at UCI and has published many articles in his field. He was in charge of unique clinics for chronic cough, eosinophilic esophagitis, and food allergy. He was a certified CME speaker for his specialty in southern California, spoke at many universities, and community hospitals on allergy topics, and was also on the national speaking circuit for various allergy and immunology initiatives. Dr. Ravi was part of the Jeffry Model Primary Immunodeficiency Clinical Center as well as the IVIG Infusion Clinic at UCI and was part of the post-graduate education committee at UCI. He is a very active member of the American Academy Of Allergy, Asthma & Immunology (AAAAI), the American College Of Allergy, Asthma & Immunology (ACAAI), and the Joint Council Of Allergy, Asthma & Immunology (JCAAI).

Romain Roncagalli obtained his Ph.D. in Molecular Biology from the University of Montreal in 2007. He is now a project leader at the Centre d’Immunologie de Marseille Luminy (CIML) and works on the molecular mechanisms underlying T cell activation. His research is based on an experimental approach combining mouse genetics, systems biology, modeling, and mass spectrometry. It has revealed the dynamic interconnection of molecules and identified new proteins and signaling circuits associated with T-cell activation.

Dr. Nazila Bahmaie was born on the 21st of December 1990 (Ahvaz, Iran). She studied BSc in Cellular and Molecular Biology (Major: Microbiology, IRAN, JULY 2013), and an MSc in Medical Microbiology (at Zanjan University of Medical Sciences, IRAN, SEPTEMBER 2016) which was supervised by Prof. Dr. Abdolreza Esmaeilzadeh. She started her scientific collaborations and academic research in 2013. She has worked as an eminent invited speaker for esteemed scientific events/international congresses and invited authors/reviewers for many scientific journals. Her research interests widely include Cancer, Cancer Immunology, Cancer Immunotherapy, Immuno-oncology, Infectious Diseases, Immunotherapy of Infectious Diseases, Immunopharmacology, Immunopharmaco-oncology, Regenerative Medicine (Clinical Applications of Immune Gene and Immune Cell-based Therapy, Drug Delivery, Monoclonal Antibodies, Vaccines, Stem Cells), Translation Medicine, and Precision Medicine with 17 scientific published articles, more than 40 presentations in national/international congresses/symposiums, and more than 10 submitted/in progress articles. Now, she is a Ph.D. candidate in Cancer Immunology at Ankara Yildirim Beyazit University, Ankara, Turkey which is supervised by Prof. Dr. Ozen Ozensoy Guler.

Farah is an Assistant lecturer of Microbiology and immunology at the Faculty of Pharmacy, Cairo University. She had a bachelor’s degree in clinical pharmacy from Cairo University in 2016. She achieved her master’s degree in Microbiology from Cairo university. She was awarded the best poster presentation recognition from the international delta university pharmacy conference 2021. She is a member of the American Society of Microbiology (ASM). She is a registered pharmacist at the Egyptian pharmacy syndicate.

Dr. Agrawal is a Professor in the Division of Basic and Clinical Immunology and is a member of the Institute of Immunology at the UC Irvine School of Medicine. She did her Ph.D. in India and moved to Paris, France on a prestigious scholarship from French Embassy for her postdoctoral work. Subsequently, she focused her research on the area of innate immunity and dendritic cells and did another postdoc at Emory Vaccine center to hone her skills. At UCI, she continued research in innate immunity specifically as it relates to aging and associated diseases. This includes immune changes that lead to Alzheimer’s disease pathogenesis and respiratory diseases.

M.Cavalcanti holds a bachelor's degree in Medical Courses from the Federal University of Rio de Janeiro (1985), a Master's degree in Medicine (Infectious and Parasitic Diseases) from the Federal University of Rio de Janeiro/UFRJ (1992), and a Doctorate in Sciences (Microbiology) from the Federal University of Rio de Janeiro/UFRJ (1999), and adjunct professor at the Serra dos Órgãos University, a physician at the Federal University of Rio de Janeiro (2005-2021). Recipient of Sandwich Doctorate Scholarships at the University of California / Los Angeles/USA (UCLA), a postdoctoral degree from Ohio State University (OSU/Ohio/USA), and improvement at Liverpool School of Tropical Medicine (LSTM/ Great Britain). MC has experience in Medicine, with emphasis on research of Infectious and Parasitic Diseases and Basic Science, in Immunology. M. Cavalcanti works mainly on the following topics: Emerging and Reemerging Infections, One Health, Coronavirus Infection and COVID-19, Zika, Chikungunya, Dengue, Schistosomes, Toxoplasmosis, HTLV-1, HIV, Inflammation and Immunity.

Will be Updated soon

Nadine Laguette studied molecular biology and genetics at the Royal Holloway College of the University of London (UK). She received her Ph.D. in cell biology from the University of Paris V in 2008. In 2009 she joined the Institute of Human Genetics (IGH) in Montpellier initially as a postdoctoral fellow where she worked on virus-host interactions. After securing a CNRS permanent position in 2012, she moved her research towards innate immunity. Since 2015, she heads a research group within the IGH that takes interest in uncovering the molecular mechanisms underlying pathological inflammation. She is the recipient of several prestigious awards and grants, including an ERC-Starting Grant and an ERC-Proof-of-concept Grant. She coordinates the FrontINov Network together with Petr Cigler.

Stephanie Buchheister studied veterinary medicine at the University of Veterinary Medicine in Hannover and subsequently graduated at Hannover Medical School in 2016, where she studied the protective mechanisms of CD14/TLR4 signaling in experimental mouse colitis models. After finishing her doctoral thesis, she continued working in the field of Inflammatory Bowel Disease research as a PostDoc. In 2017 she started working as a group leader of the health monitoring program at the Insitute for Laboratory Animal Science and Central Animal Facility at Hannover Medical School. She is responsible for the hygienic management and infection diagnostics of laboratory rodents, rabbits, cats, sheep, pigs, amphibian species, and zebrafish, maintained within complex barrier units (strict breeding and experimental barrier units, gnotobiology units, quarantine units, BSL2 barriers). Besides performing routine microbiological, parasitological, and virological diagnostic methods, her group also works on different research projects with a primary focus on molecular pathogen detection in the environmental sample material. She became a veterinarian specialist in laboratory animal medicine and is a member of a FELASA Working Group on Methodology for Health Monitoring of mice maintained in IVCs.

BachirRahoGhalem has completed his Ph.D. in 2011 from Sidi bel Abbes University. He is the Co-Director of Process Engineering and Chemistry of Solutions Laboratory, University of Mascara, Mascara, Algeria. He has published more than 50 papers in reputed journals and has been serving as an editorial board member of repute.

ELSAYED AHMED ELNASHAR, Full-Professor of textiles Apparel, Kaferelsheikh University, Egypt. Born in 19 /8/1965. Have Ph.D. 2000, Msc.1995, Bsc.1989, Helwan University. Diploma1985advanced industrial textiles institute. He holds several academic administrative positions: Dean, Vice Dean, Head of Department, He has many textile patents, Member of international scientific committees. Development of Faculties of Education commissioned by Supreme Council of Egyptian Universities. Has designed books published in Germany and Ukraine. Has published over 235 scientific Articles. Editorial board member & Reviewer for more than 225 journals, an organizer for more than 195 conferences and workshops over the world, Founder and editor of two scientific journals. And Smartex Conference Egypt. Member of the editorial board of several international journals and conferences, He has made many scientific agreements with European &Africa Universities.

I am a passionate scientist with a deeper interest in omics data analysis and pipeline development. I started my career as a Ph.D. student at the CSIR-NBRI Lucknow, India by working on variant analysis in Plants. I was also involved in various other projects as a lead bioinformatician for data analysis for nucleosomal remodeling in plants, Bulk-RNASeq data, and ChIP-Seq data. In June 2017, I joined Dr. Kristel Van steen Bio3 group, GIGA-Medical genomics, University of liege, Belgium to focus my research on marker analysis in PDAC (Pancreatic ductal adenocarcinoma) based on Bulk-RNASeq and Whole exom sequencing data of short and long term PDAC survivors. In October 2020, I joined Prof Dr. Philip Rosenstiel's group at the Institute of Clinical Molecular Biology in Kiel, Germany as a post-doctoral fellow where I got the opportunity to work on spatial transcriptome data to explore the major inflammatory bowel disease Crohn's disease and ulcerative colitis. I am also involved in AI (digital pathology) based project to work on the Whole slides (WS) images of ulcerative colitis and develop the prediction model. My deeper interest in omics data (from Bulk-RNASeq to Spatial transcriptome, AI-based models) and applying different integration approaches have driven me to interact with different people and their cultures. In my professional life, I have developed a keen attitude to learn, propose new projects, and establish techniques and protocols even if they are not used in my laboratory.

Shandar Ahmad is a Professor of Bioinformatics and former Dean at the School of Computational and Integrative Sciences, Jawaharlal Nehru since 2016. He also worked at the National Institute of Biomedical Innovation, Health, and Nutrition, Japan (2007-2016), where he still holds a Visiting Scientist honorary position. He was also an adjunct Associate Professor at the Graduate School of Frontier Bioscience, Osaka University (2008-2016). Earlier, he worked at Universiti Putra Malaysia, Universiti Kebenagansan Malaysia, and in the Department of Biosciences, Jamia Millia Islamia, New Delhi from where he quit as a Professor. Shandar Ahmad is interested in developing data-driven algorithms and applications for biological data analysis with an integrative perspective, including lead generation for early-stage drug discovery using transcriptomics data. His lab, called SciWhyLab aims to leverage his past and ongoing works in the field of sequence and structural analysis of protein-DNA and other biomolecular interactions, particularly their modeling through conventional and deep machine learning algorithms. He has experience in studying patterns of global and condition-specific gene expression, single-cell transcriptome analysis, miRNA and NGS data analysis for Influenza vaccination response, and other critical problems in the field of Biomedical research. His group has also developed deep learning algorithms to interpret ECG, EEG, and medical image data using deep learning models such as LSTM, CNN, and deep neural networks. For more, visit his website www.sciwhylab.org. Shandar Ahmad also has a deep interest in languages and poetry. He writes in English, Urdu, and Hindi, and his recent collection of English Ghazal was launched as part of the book “Dialogues with a caged parrot and Ghazal of an eavesdropper”, published by Studera Press.

Will be updated soon.

Will be updated soon.

Will be updated soon.

Dr.Sarita Shrestha is first Woman M.D Ayurveda in Nepal. Also been known as “MOTHER Ayurveda in the West”. She is the senior Ayurveda Consultant in Nepal. Worked for more than thirty years. Faculty in Mount Madonna Institute of Ayurveda College. Ca, USA for 12 years. Worked as a lecturer at Tribhuvan University and Sanskrit University for 9 years. She is an international speaker and deliberated lectures in the USA, Canada, Mexico, India, and Malaysia at different international conferences including NAMA and CAAM in the USA. Honored with national and international awards. Author of the book “Impact of Nepalese Cultural Food in Health “ Presented and published hundreds of papers. Featured in the book, “In Search of Medicine Buddha”. Feathered in “Fifty Women of Nepal who will change the World”. The way they look at, Australia Featured in “100 Women Stories” Women in leadership, Rotary, RI District 3292, Nepal-Bhutan. Featured in “Trail Blazers in Spirituality and Yoga” magazine, USA. Founder Director Devi Ma AYURVEDA Rural Hospital. Founder Chairman Devi M Kunja. Board Member Resources for Primary Health Care Center. WORKED FOR the NATIONAL RESEARCH AND TRAINING Center as a senior scientist. EX.Board member Gorkha Ayurveda Company. Founder Principal National Ayurveda College, Nepal. Founder Treasurer of Ayurveda Doctor’s Association Nepal. Ex. Member of Nepal Ayurveda Medical Council.

Dr.Ratnaprabha studied Bachelors of Ayurveda ,Professional course of 5 1/2years at the Maharastra university of health science,India and graduated as MD in Swasthvritta (Preventive and social medicine).Now persuing her Phd in same. She is working as Director of HavyaAyuevdPVT.Ltd. company in Pune,India and also as Ass.Proff. in Department of Health Sciences,PuneUniversity,India. She has vast experience in Ayurveda panchakrma and yoga nearly 12 years of experience. She also preseted her topics in many international conference like London, Spain, Portugal, Malaysia, Southkorea, Shrilanka, Nepal,etc. After being awarded by many awards on national and international level at young age, she always proud to present most ancient science in easy way. Her specialty areas are Garbhsanskar,Pregancy yoga, Ayurved skin care.Pnackarma(Detoxification),etc.